Brief: Xbrane Biopharma Q1 EBITDA Loss Narrows To SEK 32.9 Mln
05/05/2022 07:14
May 5 (Reuters) - Xbrane Biopharma AB XBRANE.ST :
* XBRANE BIOPHARMA RELEASES INTERIM REPORT FOR JANUARY –
MARCH
2022
* Q1 REVENUE AMOUNTED TO SEK 7.2M (2.5)
* Q1 EBITDA WAS SEK -32.9M (-46.8)
Source text for Eikon: ID:nMFN7wRT18
Further company coverage: XBRANE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))